JHL Biotech has announced that WeiDong Cui, Ph.D. has joined JHL Biotech as Corporate VP of Manufacturing and Technology. With the addition of WeiDong, JHL has fortified a strong leadership team. Recent JHL hires include Zack Zheng, Ph.D. as VP of Wuhan Process Development; Jason Lin as Director of Procurement; James Chang as Senior Director of Wuhan QA and Validation; and Henry Wu as Director of Corporate Projects and Wuhan Engineering. Dr. Cui has over 20 years experience in biopharmaceutical manufacturing and comes to JHL from Chempartner, where he was VP of Biologics CMC. Zack Zheng, Ph.D. joined JHL after serving as a VP at Jecho BioPharm, and he brings 16 years of experience at companies including Pfizer, Wyeth, and MedImmune. Jason Lin joined JHL after 14 years at Genentech, where he assumed procurement roles in both the United States and in China. James Chang came to JHL after 20 years in quality and management related roles at Novartis, Schering-Plough, Pfizer, and MSD. Henry Wu joined JHL after an engineering career spent at Bayer and Genentech in the San Francisco Bay Area. Zack, Jason, James, and Henry all spend a significant amount of time at JHL’s new Wuhan facility and have been instrumental in start-up of JHL’s 4x2,000L KUBio API plant, which just successfully produced a 2,000L batch of cGMP material on behalf of a client.